Avmapki Fakzynja Co-Pack blister pack (avutometinib; defactinib)
Verastem (VSTM)
Decision dateFeb 7, 2027
84 days away
Marketer take
A packaging change aimed at convenience and adherence, which gives the existing brand a patient-support message rather than a new indication.
- Sponsor company
- Verastem (VSTM)
- Indication
- KRAS-mutated recurrent low-grade serous ovarian cancer (new packaging NDA)
- Therapeutic area
- Oncology
- Event
- PDUFA target action date
- Date
- Feb 7, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?